Description

Switzerland

Business ID: L#20251050

A Swiss company with a rare license to produce weed and medical cannabis is up for sale.

The company’s purpose is the breeding, research, production, and trade of plants for medical and pharmaceutical application as well as the production, distribution, and trade of pharmaceutical and medical products.

The company may establish branch offices and subsidiaries at home and abroad, participate in other companies at home and abroad, acquire, hold, exploit, and sell intellectual property rights, and carry out all business that is directly or indirectly related to its purpose.

The company may acquire, encumber, sell, and manage real estate at home and abroad. It may also undertake financing for its own or third-party accounts, and enter into guarantees and sureties for subsidiaries and third parties.

Permits/Authorisations

The company holds all necessary permits in Switzerland for the medical cannabis sector.

Thanks to these permits, it is able to cultivate itself, store, purchase goods, import, trade, commission, and distribute its products directly within Switzerland.

The permits were granted by Swissmedic, the responsible Swiss Authorising and Controlling Authority for therapeutic products. The production facility was inspected and approved by the Cantonal Pharmacist and has been approved by the GMP (Good Manufacturing Practice) department of the Regional Institute for Medicines (RHI), thereby fulfilling all regulatory requirements for operation.

Production Field

There are 10 rooms (130sqm each) already fully operational and includes the complete GACP production as well as GMP-compliant storage and commissioning/picking.

Resellers / Network

Through its control over the entire production chain and wholesale trade, this firm has the unique opportunity to tap into the entire Swiss market for medical and pharmaceutical cannabis.

– 1,800 pharmacies in Switzerland: An experienced sales employee with established pharmacy contacts will be responsible for setting up and managing the distribution. The structure of the collaboration, whether as an independent intermediary or an employee, is currently being examined.

– Partnership with a B2B Pharmaceutical Wholesaler (e.g., Galexis and Co.). Existing contacts create a promising basis for inclusion in Galexis’ product range.

Licence

Infrastructure

The company benefits from a cost-efficient production by leasing space and being able to optimally utilize the existing infrastructure.

Its landlord recently offered it the prospect of leasing additional space in the building. A 10-year rental agreement has been secured at very favorable conditions.

Human Resources

There are 2 employees and 3 freelancers. Its team has been in place for 10 years and possesses comprehensive experience.

Rapid Scalability

Thanks to the existing know-how and the possibility of leasing additional production space the company can quickly respond to demand.

Swiss Made

This allows it to access the international market with its high-quality flowers. To the company’s knowledge, no Swiss player is currently active on the global market with their own products.